---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-017398"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:47:36.988897+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech Q1 revenue $15.5M, up 99% YoY; net loss narrows to $1.2M

## Summary
- Net revenues $15.5M (99% YoY increase); net loss $1.2M vs $3.2M prior year.
- Gross margin 86% vs 90% prior year due to lower margins on Scendia products.
- SG&A $13.0M (up $3.6M) driven by higher sales commissions and sales force expansion.
- Scendia sales flat at $3.0M; ALLOCYTE supply issues persist, expected resolution H2 2023.
- Received 510(k) clearance for BIASURGE Advanced Surgical Solution; preparing launch late 2023.

## SEC filing metadata
- accession: 0001493152-23-017398
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315223017398/0001493152-23-017398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315223017398/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-017398
- JSON: https://secwatch.observer/filing/0001493152-23-017398.json
- Plain text: https://secwatch.observer/filing/0001493152-23-017398.txt

## Key facts
- Earnings Releases
  Sanara MedTech Inc. reported the quarter ended March 31, 2023 results: revenue $15.5 million, net income net loss of $1.2 million.
  - Period: the quarter ended March 31, 2023
  - Revenue: $15.5 million
  - Net income: net loss of $1.2 million
  - Result: reported results
  source text: clearance for BIASURGETM. First Quarter 2023 Consolidated Financial Results (Unaudited) ● Net Revenues. For the three months ended March 31, 2023, we generated net revenues of $15.5 million compared to net revenues of $7.8 million for the three months ended March 31, 2022, a 99% increase from the prior year period. Our net revenues for the three months ended March
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315223017398/0001493152-23-017398-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.